Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

RARITAN, N.J., Dec. 9, 2022 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for t... Biopharmaceuticals, Oncology Janssen Pharmaceutical Companies, Johnson & Johnson, talquetamab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news